Publications
] "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In Molecular Therapy, S126-S127. Vol. 22. 2014.
"Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage." Proceedings of the National Academy of Sciences of the United States of America 111, no. 9 (2014): E798-E806.
"Special issue on engineered DNA-binding proteins." Acs Synthetic Biology 3, no. 10 (2014): 702-703.
"Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies." Accounts of Chemical Research 47, no. 8 (2014): 2309-2318.
"Tissue-engineered cartilage with inducible and tunable immunomodulatory properties." Biomaterials 35, no. 22 (2014): 5921-5931.
"Tissue-engineered cartilage with inducible and tunable immunomodulatory properties." Biomaterials 35, no. 22 (2014): 5921-5931.
"Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis." Scientific Reports 4 (2014).
"59. Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
"Anatomically-Shaped Tissue-Engineered Cartilage with Tunable and Inducible Anti-Inflammatory Capabilities." In Tissue Engineering. Part A, S330. Vol. 21. 2015.
"Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
"Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy : the Journal of the American Society of Gene Therapy 23, no. 3 (2015): 523-532.
"CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." In Tissue Engineering. Part A, S170. Vol. 21. 2015.
"Enabling functional genomics with genome engineering." Genome Research 25, no. 10 (2015): 1442-1455.
"Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain." Acs Synthetic Biology 4, no. 6 (2015): 689-699.
"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers." Nat Biotechnol 33, no. 5 (2015): 510-517.
"Genome editing: the end of the beginning." Genome Biology 16 (2015).
"Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators." Genome Res 25, no. 8 (2015): 1158-1169.
"Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements." Nat Methods 12, no. 12 (2015): 1143-1149.
"Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells." Tissue Engineering. Part A 21, no. 7-8 (2015): 1261-1274.
"A light-inducible CRISPR-Cas9 system for control of endogenous gene activation." Nature Chemical Biology 11, no. 3 (2015): 198-200.
"Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy." Nature Communications 6 (2015): 6244-.
"Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
"Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum." Nat Neurosci 18, no. 5 (2015): 647-656.
"Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment." Integrative Biology : Quantitative Biosciences From Nano to Macro 7, no. 6 (2015): 663-671.
"Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic Acids Research 43, no. 18 (2015): 8924-8941.